Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Sues US FDA To Obtain 180-Day Exclusivity For Its Generic Restasis

Executive Summary

Complaint challenges agency's revised definition of "first applicant," which does not require notice of Paragraph IV certification to obtain exclusivity.

You may also be interested in...



Legal News: Teva V. FDA, Pay-For-Delay, Citizen Petitions, User Fee Scheme

US court tosses Teva suit seeking generic Restasis exclusivity. FTC loses appeal challenging Shire's citizen petitions, settles Solvay pay-for-delay case. DoJ resolves FCA case alleging company made deal to avoid paying FDA user fees for two NDAs.

Indivior's New Suboxone Patent Cannot Keep Dr. Reddy's Generic Off Market

US Federal Circuit applies new standard in finding continuation patent claims are indistinct from those in parent patent, vacates preliminary injunction.

Indivior's New Suboxone Patent Cannot Keep Dr. Reddy's Generic Off Market

US Federal Circuit applies new standard in finding continuation patent claims are indistinct from those in parent patent, vacates preliminary injunction.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS124099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel